Background: Osteopontin (OPN) is a glycoprotein. It is found in several biological fluids. OPN can be detected in plasma or serum, was found to be upregulated in several patients with hyperthyroidism and down regulated in hypothyroid patients so it may represent a new biomarker. Objective: The objective of this study was designed to investigate the evaluation of serum osteopontin levels with clinical parameters of thyroid hormone dysfunction. Materials and Methods: The present study was conducted on 50 hypothyroid (Group II) and 50 hyperthyroid(Group III) patients attending the Medical OPD and Radio Immuno Assay (RIA) Laboratory of the Biochemistry Department of JLN Medical College & Hospital, Ajmer. The results of patients were compared with 50 healthy control (Group I) subjects of either sex of age group(15-55years). Serum levels of FT3, FT4 and OPN were measured by ELISA and TSH was measured by RIA method, after taking approval from ethical committee. Results: The mean serum Osteopontin (OPN) level was observed statistically highly significant increase (p value< 0.0001) in hyperthyroid subjects and statistically highly significant decrease (p value< 0.0001) in hypothyroid subjects when compared with healthy controls. Conclusions: This study indicates that osteopontin might be useful as a novel prognostic biomarker in patients with thyroid dysfunction.
